GTHP - Guided Therapeutics Inc.

PinkSheets traded GTHP - Guided Therapeutics Inc., like TooNiceStocks has always done in the past, became a MULTI-DAY RUNNERS. After we initiated coverage on GTHP volume started to pour in and our article was picked up by all the respectable news outlets. Shares have since exploded in 2 days totaling of 30%+. Slow and Steady gains without the worry of course. Clearly this has been a huge success and this looks to continue as PIVOTAL FDA DATA is being presented by 5 well respected Doctors in the field of Cervical Cancer next week. Our world famous due diligence alert on GTHP was sent to our members and guess what happened next? You guessed right, an instant shot of adrenaline kicked in, sending shares up 20% the first day and 10% the next day, hitting an intraday high of $1.45 or yielding a potential 37% return on investment in literally 2 days.  

TooNiceStocks.com Initiates Coverage on Guided Therapeutics Inc. (PINK: GTHP)

GTHP @ $1.08 High $1.45 = 37% Multi-Day Runner  

FoxBusiness News

http://www.foxbusiness.com/story/markets/industries/finance/toonicestocks-initiates-coverage-upcoming-crucial-fda-cinical-trial-results/

Trading Markets

http://www.tradingmarkets.com/news/press-release/ccdc_gthp_toonicestocks-initiates-coverage-on-upcoming-crucial-fda-clinical-trial-results-for-guided-therapeut-849225.html

PinkSheets traded GTHP - Guided Therapeutics Inc. (GT) announced on 2/23/2010, their upcoming release of crucial results of the U.S. Food and Drug Administration (FDA) pivotal clinical trial for their LightTouch(TM) Non-invasive Cervical Cancer Detection System. TooNiceStocks sees a bullish rally occurring as this revolutionary Cancer Detection System has 5 leading doctors scheduled to present at the American Society for Colposcopy and Cervical Pathology biennial meeting, taking place from March 24 - 27, 2010, in Las Vegas, NV.

Technicals: Guided Therapeutics Inc. definitely has the breakout potential.  If we look back to the chart in November 2009, a bullish outbreak occurred on 11/23/09 and GT reached a 52-week high of $1.70. Can GT be an easy double from this point? With the looming FDA data next week and a low float of shares in the public, this might very well be the case.  Looking back 30 days, GT has moved up comfortably from $.80 to an intraday high of $1.10 recently. GT is trading above its 13 day moving average, which is considered to be the sign of a bullish trend. In addition, there is added weight to this indication because the moving average is rising and suggests that there has been buying interest in this stock. GT closed above the trigger point for the Parabolic SAR and is currently registering a bullish signal.

Due Diligence: Guided Therapeutics Inc. currently sits on 16 U.S. Patents (You can view all 16 patents in detail by viewing the full due diligence report at www.TooNiceStocks.com). If the results of the FDA pivotal clinical trial data are impressive, we will see GT jump leaps and bounds. Should the panel of 5 leading doctors agree that LightTouch(TM) is adequate, then perhaps they have a breakthrough. The Cervical Cancer Market is immense and shows no signs of slowing down in the cancer market. Marketresearch.com states that, “forecasts show significant growth until 2016, GlobalData has estimated the global cervical cancer market to be valued at $1.8 billion in 2009. It is expected to grow to $4.1 billion by 2016, at a Compound Annual Growth Rate (CAGR) of 11.9% between 2009 and 2016.” This growth is primarily attributed to increased competition among the existing cervical cancer treatments, vaccines, and detection systems in the market. On the financing side, the National Cancer Institute granted GT $2.5 Million to commercialize noninvasive cervical cancer detection devices. Furthermore GT recently received new funding commitment from Konica Minolta Opto, Inc. in expanding cancer detection product lines, a commitment expected to be worth $1.59 Million over a 12 month period. Most importantly in the BusinessWire news release, Mark L. Faupel, Ph.D., President and CEO of GT stated “We are pleased that the presentation authors, all of whom are leaders in women’s health care, support the LightTouch technology and have agreed to speak to its potential for the early detection of cervical cancer.”

“Finding Value in the Undervalued.” – www.TooNiceStocks.com

TooNiceStocks.com was not compensated, rather we have initiated our own independent research. As always read full disclaimer.